Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Eribulin
Drug ID BADD_D00798
Description Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for use in the treatment of advanced solid tumors [A7439].
Indications and Usage For the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic cancer.
Marketing Status Prescription
ATC Code L01XX41
DrugBank ID DB08871
KEGG ID D08914
MeSH ID C490954
PubChem ID 11354606
TTD Drug ID D0XQ5X
NDC Product Code Not Available
Synonyms eribulin | E 7389 | E-7389 | ER-086526 | ER086526 | ER 086526 | ER-86526 | Halaven | NSC 707389 | NSC707389 | NSC-707389 | B 1793 | B-1793 | B 1939 | B-1939 | eribulin mesylate | eribulin monomethanesulfonate | eribulin mesilate | eribulin (as mesylate)
Chemical Information
Molecular Formula C40H59NO11
CAS Registry Number 253128-41-5
SMILES CC1CC2CCC3C(=C)CC(O3)CCC45CC6C(O4)C7C(O6)C(O5)C8C(O7)CCC(O8)CC(=O)CC9C(CC(C1=C)O 2)OC(C9OC)CC(CN)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal distension07.01.04.001--
Abdominal pain07.01.05.0020.003463%
Abdominal pain upper07.01.05.003--
Alanine aminotransferase increased13.03.01.0030.001066%
Alopecia23.02.02.0010.006127%
Altered state of consciousness19.07.01.003; 17.02.04.0010.000533%Not Available
Anaemia01.03.02.0010.010656%
Angioedema23.04.01.001; 10.01.05.009--Not Available
Aphasia19.21.01.001; 17.02.03.0010.000799%
Aphthous ulcer07.05.06.0020.000799%Not Available
Aplasia08.03.04.003; 03.02.01.0020.000533%Not Available
Arthralgia15.01.02.001--
Arthritis15.01.01.0010.000533%
Ascites09.01.05.003; 07.07.01.001; 02.05.04.0020.001332%
Aspartate aminotransferase increased13.03.01.0060.001332%
Asthenia08.01.01.0010.007193%Not Available
Atelectasis22.01.02.0010.000533%
Back pain15.03.04.005--
Blood creatinine increased13.13.01.004--
Blood glucose increased13.02.02.002--Not Available
Body temperature increased13.15.01.001--Not Available
Bone pain15.02.01.001--
Bronchitis22.07.01.001; 11.01.09.001--
C-reactive protein increased13.09.01.0070.001865%Not Available
Cardiac failure02.05.01.0010.000834%
Cataract06.06.01.0010.000533%
Cellulitis23.09.01.001; 11.02.01.0010.001332%Not Available
Cerebral haemorrhage24.07.04.001; 17.08.01.003--Not Available
Cerebral infarction24.04.06.002; 17.08.01.0040.001332%Not Available
Chest discomfort22.02.08.001; 08.01.08.019; 02.02.02.009--Not Available
The 1th Page    1 2 3 4 5    Next   Last    Total 9 Pages